Skip to main content

Advertisement

SpringerLink
Log in

Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

The hepatitis C virus (HCV) is a major cause of illness around the world. HCV genotype 3a is the most prevalent genotype in Thailand. Direct-acting antiviral (DAA) drugs are available for treatment, and these drugs target the NS3, NS5A, and NS5b proteins of HCV. However, HCV variants that are resistant to NS3 protease inhibitors have been found during treatment. This resistance can be naturally occurring or in response to treatment. The purpose of this study is to analyze the codon positions of the main mutation of the partial NS3 gene region of HCV genotype 3a.

Methods

In order to detect mutations and confirm the genotype of HCV genotype 3a, the nucleotide sequencing and amino acid portion of NS3 were analyzed.

Results

Twenty-six samples were successfully sequenced and clustered within two sub-clades defined as 3a-1 and 3a-2. Through amino acid mutation analysis, the variations were detected at codon positions 122 (3.8%), 132 (84.6%), 168 (100%), 170 (92.3%), 174 (100%), and 175 (100%).

Conclusions

In conclusion, mutations at positions 168, 170, 174, and 175 of the NS3 region are common within the HCV genotype 3a. This information should be useful in the development of effective anti-viral drugs that can successfully treat HCV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453–463

    Article  CAS  PubMed  Google Scholar 

  2. Nakano T, Lau GMG, Lau GML, Sugiyama M, Mizokami M (2012) An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 32:339–345

    Article  CAS  PubMed  Google Scholar 

  3. Global progress report on HIV, viral hepatitis and sexually transmitted infections (2021) (https://www.who.int/publications/i/item/9789240027077, accessed 4 Jun 2022.

  4. Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH (2021) Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS ONE 16:e0251673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965

    Article  CAS  PubMed  Google Scholar 

  6. Kowdley KV (2005) Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 39(1 Suppl):S3–8

    Article  CAS  PubMed  Google Scholar 

  7. European Association for the Study of the Liver, Electronic address, e.e.e. and European Association for the Study of the, L (2018) EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69:461–511

  8. Feld JJ, Jacobson IM, Hézode C et al (2015) Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 373:2599–2607

    Article  CAS  PubMed  Google Scholar 

  9. Kwo PY, Poordad F, Asatryan A et al (2017) Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 67:263–271

    Article  CAS  PubMed  Google Scholar 

  10. Lawitz E, Poordad F, Gutierrez JA et al (2017) Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology 65:439–450

    Article  CAS  PubMed  Google Scholar 

  11. Irekeola AA, Ear ENS, Mohd Amin NAZ, Mustaffa N, Shueb RH (2022) Antivirals against HCV infection: the story thus far. J Infect Dev Ctries 16:231–243

    Article  CAS  PubMed  Google Scholar 

  12. Gonzales Zamora JA (2018) Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida. Diseases 6:51

    Article  PubMed Central  Google Scholar 

  13. Sistayanarain A, Kunthalert D, Vipsoongnern Y (2011) A shift in the hepatitis C virus genotype dominance in blood donor samples from Thailand. Mol Biol Rep 38:4287–4290

    Article  CAS  PubMed  Google Scholar 

  14. Sistayanarain A, Chaiwong S (2017) Molecular characterization of hepatitis C virus genotype 6 subtypes in Thai blood donors. J Microbiol Immunol Infect 50:26–31

    Article  CAS  PubMed  Google Scholar 

  15. Bourliere M, Barberin JM, Rotily M et al (2002) Epidemiological changes in hepatitis C virus genotypes in France evidence in intravenous drug users. J Viral Hepat 9:62–70

    Article  CAS  PubMed  Google Scholar 

  16. Zein NN, Rakela J, Krawitt EL et al (1996) Hepatitis C virus genotypes in the United State: epidemiology, pathogeneicity, and response to interferon therapy. Ann Intern Med 125:634–639

    Article  CAS  PubMed  Google Scholar 

  17. Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, André-Garnier E (2012) Genotyping and resistance profile of hepatitis C (HCV) genotypes 1–6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods 185:94–100

    Article  CAS  PubMed  Google Scholar 

  18. Pickett BE, Striker R, Lefkowitz EJ (2011) Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 18:608–618

    Article  CAS  PubMed  Google Scholar 

  19. Vicenti I, Rosi A, Saladini F et al (2012) Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 67:984–987

    Article  CAS  PubMed  Google Scholar 

  20. Peres-da-Silva A, Almeida AJ, Lampe E (2012) Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs. Mem Inst Oswaldo Cruz 107:254–261

    Article  CAS  PubMed  Google Scholar 

  21. De Luca A, Di Giambenedetto S, Lo Presti A et al (2015) Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infect Dis 2:ofv043

    Article  PubMed  PubMed Central  Google Scholar 

  22. Gaudieri S, Rauch A, Pfafferott K et al (2009) Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49:1069–1082

    Article  CAS  PubMed  Google Scholar 

  23. da Silva DL, Nunes HM, Freitas PEB (2021) Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil. Virus Res 292:198251

    Article  PubMed  Google Scholar 

  24. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O (2013) Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol 19:8940–8948

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Li Z, Chen ZW, Li H, Ren H, Hu P (2017) Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 10:377–392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 65:50–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chen ZW, Li H, Ren H, Hu P (2016) Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep 6:20310

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Palanisamy N, Danielsson A, Kokkula C et al (2013) Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 99:12–17

    Article  CAS  PubMed  Google Scholar 

  29. Paolucci S, Fiorina L, Piralla A et al (2012) Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol J 9:245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lontok E, Harrington P, Howe A et al (2015) Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62:1623–1632

    Article  PubMed  Google Scholar 

  31. Pawlotsky JM (2016) Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 151:70–86

    Article  CAS  PubMed  Google Scholar 

  32. Douglas MW, Tay ESE, Wang DS et al (2020) Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatol Commun 4:904–915

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Di Stefano M, Faleo G, Farhan Mohamed AM et al (2021) Resistance Associated Mutations in HCV Patients Failing DAA Treatment. New Microbiol 44:12–18

    CAS  PubMed  Google Scholar 

  34. Hoffmann L, Faffe DS, Lima JF et al (2015) No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy. BBA Clin 3:146–151

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sarrazin C (2021) Treatment Failure with DAA Therapy: Importance of Resistance. J Hepatol 74:1472–1482

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank National blood centre, The Thai Red Cross Society, Bangkok, Thailand for providing the samples. The project was supported by National Science, Research and Innovation Fund (NSRF), Year 2021 (R2564B008). Thank you to Mr. Paul Freund of Naresuan Univerisity Writing Clinic (DIALD) for editing assistance.

Author information

Authors and Affiliations

  1. Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand

    Anusorn Kiattanaphon, Duangkamol Kunthalert & Anchalee Sistayanarain

  2. National blood centre, The Thai Red Cross Society, Bangkok, Thailand

    Yaovaluk Vipsoongnern

Authors
  1. Anusorn Kiattanaphon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaovaluk Vipsoongnern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Duangkamol Kunthalert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anchalee Sistayanarain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anchalee Sistayanarain.

Ethics declarations

Conflict of interest

All authors declare no conflicts of interest.

Ethical approval

Study protocols and procedures were reviewed and approved by the Naresuan University Institutional Review Board (IRB number P10179/63) and the Thai Red Cross Society National Blood Center (Protocal number: 25/2563).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kiattanaphon, A., Vipsoongnern, Y., Kunthalert, D. et al. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a. Mol Biol Rep 49, 9437–9443 (2022). https://doi.org/10.1007/s11033-022-07803-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-022-07803-5

Keywords

Search

Navigation